Very recently, we identified FoxM1 expression in tumor tissues as an independent prognostic factor affecting recurrence of HCC and overall survival of HCC patients following surgery, indicating that FoxM1 might not only be a promising therapeutic target but also a prognostic biomarker for HCC [23]. This evidence concerns the gene FOXM1 and hepatocellular carcinoma.